| CPC A61K 47/6849 (2017.08) [A61K 47/6803 (2017.08); A61P 35/00 (2018.01); C07K 16/2803 (2013.01)] | 38 Claims |
|
1. An antibody conjugate comprising General Formula I, or a pharmaceutically acceptable salt thereof:
Ab-(X)y [General Formula I]
wherein:
Ab is an anti-ROR1 antibody, or an antigen-binding fragment thereof,
the antibody or antigen-binding fragment thereof comprises a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein,
(a) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 1, 6 and 14, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 22, 30 and 38, respectively;
(b) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 2, 7 and 15, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 23, 31 and 39, respectively;
(c) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 1, 8 and 16, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 24, 32 and 40, respectively;
(d) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 3, 9 and 17, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 25, 33 and 41, respectively;
(e) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 1, 10 and 18, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 26, 34 and 41, respectively;
(f) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 4, 11 and 19, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 27, 35 and 42, respectively;
(g) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs 5, 12 and 20, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs 28, 36 and 41, respectively;
(h) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 3, 13 and 21, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 29, 37 and 41, respectively;
(i) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 2, 96 and 15, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 23, 31 and 39, respectively; or
(i) CDRH1, CDRH2 and CDRH3 comprise the amino acid sequence of SEQ ID NOs. 3, 9 and 97, respectively, and CDRL1, CDRL2 and CDRL3 comprise the amino acid sequence of SEQ ID NOs. 25, 33 and 41, respectively
each X is independently selected from a moiety that comprises at least one active agent and a linker, wherein the linker couples Ab to the at least one active agent;
wherein the linker links Ab and the at least one active agent; and
y is an integer from 1 to 20.
|